文献速递心境障碍睡眠障碍

通过失眠治疗减少自杀意念(REST-IT):一项随机临床试验

Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial.
PubMed 文献 · Am J Psychiatry · 2019-09-20

REST-IT 是一项为期8周、三中心、双盲、安慰剂对照的平行组随机试验,共纳入103名18-65岁、未用药、患有重性抑郁障碍、失眠及自杀意念的受试者,比较控释唑吡坦联合开放标签SSRI与安慰剂联合SSRI的效果。结果显示,控释唑吡坦对失眠有显著改善,但在自杀意念量表(SSI)上未观察到显著治疗效应,而在哥伦比亚自杀严重程度评定量表(C-SSRS)上观察到显著治疗效应,且失眠越严重者获益越明显。结论不支持对所有抑郁伴失眠门诊患者常规处方催眠药以缓解自杀意念,但提示在抗抑郁药起始阶段联合催眠药可能对自杀门诊患者有益,尤其是失眠严重者。

要点

  • 控释唑吡坦显著改善失眠,尤其对失眠最严重者效果明显。
  • SSI未显示显著治疗效应,但C-SSRS显示控释唑吡坦显著降低自杀意念。
  • 失眠改善与自杀意念减轻显著正相关,失眠越严重者获益越大。

核心结论

  • 结果不支持对所有抑郁伴失眠门诊患者常规处方催眠药以缓解自杀意念。
  • 在抗抑郁药起始阶段联合催眠药可能对自杀门诊患者有益,尤其失眠严重者。

研究设计与样本

  • REST-IT为8周三中心双盲安慰剂对照平行组随机试验,比较控释唑吡坦与安慰剂,均联合开放标签SSRI。
  • 受试者为18-65岁未用药、重性抑郁障碍伴失眠及自杀意念者,共103人随机分配(唑吡坦-CR组51人,安慰剂组52人;64女39男;平均年龄40.5岁)。

主要发现

  • 控释唑吡坦对失眠有显著改善作用,尤其对失眠症状最严重者效果明显。
  • SSI未观察到显著治疗效应(最小二乘均值估计=-0.56,SE=0.83,95%CI=-2.19, 1.08)。
  • C-SSRS显示控释唑吡坦有显著治疗效应(最小二乘均值估计=-0.26,SE=0.12,95%CI=-0.50, -0.02)。
  • 控制其他抑郁症状影响后,SSI评分下降与失眠改善显著正相关。
  • C-SSRS上控释唑吡坦降低自杀意念的优势在失眠更严重者中更大;无死亡或自杀企图发生。

关键数值与推荐

  • 主要结局为自杀意念,首先采用自杀意念量表(SSI)测量,其次采用哥伦比亚自杀严重程度评定量表(C-SSRS)测量。

临床怎么用

  • 不应将催眠药常规用于所有抑郁伴失眠门诊患者以缓解自杀意念。
  • 对自杀门诊患者,尤其在抗抑郁药起始阶段且失眠严重者,可考虑联合催眠药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors sought to determine whether targeted treatment of insomnia with controlled-release zolpidem (zolpidem-CR) in suicidal adults with insomnia would provide a reduction in suicidal ideation superior to placebo. METHODS: Reducing Suicidal Ideation Through Insomnia Treatment was an 8-week three-site double-blind placebo-controlled parallel-group randomized controlled trial of zolpidem-CR hypnotic therapy compared with placebo, in conjunction with an open-label selective serotonin reuptake inhibitor. Participants were medication-free 18- to 65-year-olds with major depressive disorder, insomnia, and suicidal ideation. Suicidal ideation was the main outcome, measured first by the Scale for Suicide Ideation and second by the Columbia-Suicide Severity Rating Scale (C-SSRS). RESULTS: A total of 103 participants were randomly assigned to receive zolpidem-CR (N=51) or placebo (N=52) (64 women and 39 men; mean age=40.5 years). Zolpidem-CR had a robust anti-insomnia effect, especially in patients with the most severe insomnia symptoms. No significant treatment effect was observed on the Scale for Suicide Ideation (least squares mean estimate=-0.56, SE=0.83, 95% CI=-2.19, 1.08), but the reduction in scores was significantly positively related to improvement in insomnia after accounting for the effect of other depression symptoms. The C-SSRS indicated that zolpidem-CR had a significant treatment effect (least squares mean estimate=-0.26, SE=0.12, 95% CI=-0.50, -0.02). The advantage for zolpidem-CR in reducing suicidal ideation on the C-SSRS was greater in patients with more severe insomnia. No deaths or suicide attempts occurred. CONCLUSIONS: Although the results do not support the routine prescription of hypnotic medication for mitigating suicidal ideation in all depressed outpatients with insomnia, they suggest that coprescription of a hypnotic during initiation of an antidepressant may be beneficial in suicidal outpatients, especially in patients with severe insomnia.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. McCall WV, Benca RM, Rosenquist PB, et al. Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial. Am J Psychiatry. 2019. PMID: 31537089. doi:10.1176/appi.ajp.2019.19030267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。